billHR7655Event Monday, May 11, 2026Analyzed

Support for Expectant and Parenting Foster Youth Act

Neutral

Summary

The Support for Expectant and Parenting Foster Youth Act (HR7655) is a procedural authorization bill that amends the Social Security Act to improve coordination between child welfare and the Maternal, Infant, and Early Childhood Home Visiting Program. It authorizes no direct spending and does not create a procurement or contracting mechanism that would materially affect any publicly traded company.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HR7655 authorizes zero dollars in new spending — it simply amends administrative requirements for existing child welfare programs.
  • 2.No publicly traded companies are named, referenced, or impacted by any provision in the bill.
  • 3.The bill does not create any contract, grant, or procurement mechanism that would affect corporate revenues.

Market Implications

There are no market implications from this legislation. It does not affect any public company's revenue, costs, or competitive dynamics. Retail investors should not consider this bill in any sector allocation or stock selection decision.

Full Analysis

1. **What happened and its current status:** On 2026-05-11, HR7655 was placed on the Union Calendar after being reported (amended) by the House Committee on Ways and Means on 2026-05-11. The bill was introduced on 2026-02-24 by Rep. Yakym (R-IN-2) with 3 cosponsors. It is currently in active status, awaiting floor consideration in the House. The Senate companion bill (S. 4805) has not advanced. The legislative velocity is moderate — the bill moved through committee with a 41-0 bipartisan vote, but remains in the early stage of floor passage. 2. **The money trail:** This bill authorizes no funding. It amends Section 477 of the Social Security Act to require state plans to certify processes for connecting expectant and parenting foster youth with existing evidence-based home visiting services under Section 511 of the same Act. It also allows states to use existing federal IV-E funds for tailored case management. No new appropriations are created or authorized. The effective date is one year after enactment, allowing states time to adjust administrative processes. 3. **Structural winners and losers:** This bill affects state and tribal child welfare agencies — no publicly traded companies are directly impacted. The home visiting services referenced are predominantly delivered by non-profit organizations, state health departments, and community-based organizations. No defense, technology, energy, or financial sector involvement exists. 4. **Market implications:** There are no market implications from this bill. It does not change the regulatory landscape for any publicly traded company. It does not create new contract opportunities, tax credits, or procurement mandates. It does not affect trade policy, tariffs, or market access. 5. **Timeline:** The bill must pass the full House, then the Senate, and be signed by the President to become law. With only 3 cosponsors and no Senate companion bill advanced, passage in the 119th Congress remains uncertain but possible given the bipartisan committee vote.

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderApr 30, 2026

Promoting Efficiency, Accountability, and Performance in Federal Contracting

This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.